We have seen an uptick in reactions to Emend, with two in April (1.5% of cases) and four in June (7.7% of cases). Reactions included chest tightness, facial flushing, and itching.

Has anyone else noticed an increased incidence of Emend reactions?

NDC: 72205-083-01
Lot: CSE09034A
Exp: 8/31/27

NDC: 72205-083-01
Lot: CSE10035A
Exp: 9/30/27

Hi all,

Can you share guidance for dilution instructions of oral potassium chloride solution in pediatric patients? Manufacturers of 20 meq/ 15ml formulation recommend diluting in at least 120 ounces of water, which is too much fluid for most of our pediatric patients. What is your current dilution instructions for neonates and pediatric patients?

Thank you in advance,

Mirella Cardarelli

Hi all-

What is your standard workflow for drug library utilization when the patient comes from the OR to recovery? Do you have an "anesthesia mode" on your pumps that allow for no guardrails, and the expectation is that nursing switch over to whatever appropriate care area once in recovery/patient is stable? Or do you have an alternate workflow? Thanks in advance for your thoughts!

Liz Rebo

Hello MSOS Members! For those attending the upcoming ASHP Pharmacy Futures meeting in Charlotte, NC, ISMP's session will be this Sunday 1:30 - 2:30 pm ET in Room E219A Level 2. We will also have an informal meet and greet from 2:45 - 3:45 pm ET in Room 218 Level 2. Hope to see you there!

Hello everyone,

For any hospitals with over 300 beds, what is your med safety reporting/meeting structure?

Do you have a separate Med Safety committee? If yes, what is its oversight committee? Does it go to P&T, another overall hospital quality group, or something else?

Or is your Med Safety report out/discussion part of a different group (i.e., not a stand alone committee). In this case, how do you organize report outs vs granular safety event discussions?

Any information/details would be greatly appreciated.

Thank you!

-Saduf

Hi Everyone,

I'm reaching out with a question raised by our IV team regarding the placement of labels on compounded IVPB products.

Specifically, where do you place the IV label—on the front or the back of the bag? If placed on the front, does the label cover the name of the diluent? Currently, our practice is inconsistent—some technicians place the label on the front of the IVPB, while others apply it to the back. When placed on the front, the label sometimes covers the name of the diluent, which has led to questions about whether this is preferred or should be avoided.

We have identified opportunities with Ultomiris/Soliris REMS requirements, noteably with:
• Meningococcal vaccine series prior to administration, booster after 1 year, and every 2-3 years after
• Antimicrobial prophylaxis required if above not met

We are interested to see what other sites are doing to ensure compliance.
Thanks!
Maria Cumpston, PharmD, CPPS
Medication Safety Officer & Compliance Director
WVU Hospitals
304-598-4000 ext 73356

Hi,
Wanted to get some insight on how other hospitals handle ordering pre- procedure medications? Are they ordered as 'once' orders? or 'once PRN'? We have had some errors in both instances. With the 'once' orders, sometimes these medications get given too early (ie. surgical prophylaxis antimicrobials) but with the 'once PRN' medications, we have had instances where the medication is not given.
Thanks!

Any cardiac centers willing to share their setup/default settings for ordering a titratable dobutamine and/or milrinone here or via fiona.lui@swedish.org

Providers at my institution have proposed that:

-Dobutamine dosing range should be limited 0-10 mcg/kg/min despite Lexicomp's dosing range of 0-20 mcg/kg/min.

-Milrinone dosing range should not exceed 0.375 mcg/kg/min despite Lexicomp's range: 0.125 - 0.75 mcg/kg/minute.

Do you store concentrated electrolytes in your pharmacy carousel? If yes, what safeguards do you have implemented?